Abstract
The rapidly growing market of biopharmaceuticals is opening new opportunities for biologics and biosimilar products especially in the vaccine therapeutics. As more and more products in this area are off the patents, the companies are looking to introduce biosimilar vaccines in the market. The challenges are enormous, and it is not easy to create a generic version of vaccine, as it was done for commonly used dosage forms like tablets, capsules, and so on. Biosimilar and biosimilarity are not synonymous, which means there are no clinically significant differences between the biological product and the standard product in terms of the safety, purity, and potency of the product. This chapter discusses the stepwise manufacturing and characterization of biosimilar vaccines, clinical studies, and safety and efficacy studies for such biosimilar vaccines. Biosimilar vaccine products and reference products are generated in the living cells and require trained expertise, as well as technology in manufacturing biosimilar products, which are usually highly effective compared to small-molecule drugs. The Food and Drug Administration (FDA)'s regulatory authority for the approval of biosimilar products is under Public Health Service Act; however, the approval of biosimilar products is also suggested to be regulated under the Federal Food, Drug, and Cosmetics Act (FD&C).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.